<- Go Home

Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

Market Cap

$33.5B

Volume

1.1M

Cash and Equivalents

$1.1B

EBITDA

$2.5B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$7.3B

Profit Margin

75.49%

52 Week High

$319.76

52 Week Low

$189.44

Dividend

N/A

Price / Book Value

2.20

Price / Earnings

28.71

Price / Tangible Book Value

47.74

Enterprise Value

$39.3B

Enterprise Value / EBITDA

14.72

Operating Income

$2.0B

Return on Equity

8.05%

Return on Assets

4.86

Cash and Short Term Investments

$1.1B

Debt

$6.9B

Equity

$15.2B

Revenue

$9.7B

Unlevered FCF

$1.1B

Sector

Biotechnology

Category

N/A

Company Stock Pitches